Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Inclusion Criteria: * Active SLE disease#and at least according with 4 of the 11 items of the American College of Rheumatology (ACR) criteria 1997. * Age \& Gender: Male or female between 18 and 65 years of age inclusive#and the sex ratio is not limited * Signed informed consent form#willing or able to participate in all required study evaluations and procedures. * SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index) score ≥ 8 during the screening period.and if there is Hypo-complement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be at least 6 at screening . * Autoantibody-positive * on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted of any of the following (alone or in combination): cortical hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate Exclusion Criteria: * kidney disease ：Severe lupus nephritis 8 weeks prior to randomization (designed as:Urine protein\>6g/24h or serum creatinine ( SCr\>2.5mg/dL or 221umol/L ) or needing for hemodialysis or receipting high dose cortical hormone ≥14 days( metacortandracin\>100mg/d or equivalent) * Central nervous system disease caused by SLE or non SLE 8 weeks prior to randomization (including epilepsy、 mental disease、organic encephalopathy syndrome、cerebrovascular accident, encephalitis, central nervous system vasculitis; * there are serious heart, liver, kidney and other important organs and blood, endocrine system diseases and medical history; Evaluation criteria for severity : 1. Alanine aminotransferase#ALT#or aspartate aminotransferase (AST) ≥2 upper limit of normal (ULN); 2. Creatinine Clearance (Ccr)\<30ml/min; 3. White Blood Cell Count(WBCs)\<2.5x 10(9)/L; 4. hemoglobin\<85g/L; 5. Platelets\<50x 10(9)/L. * Have a historically active hepatitis or active hepatitis or medical history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C: Patients with hepatitis C antibody positive are excluded; * Immune deficiency, uncontrolled severe infection and patients with active or recurrent peptic ulcer; * Pregnant , lactating women and men or women who have birth plans in the past 12 months ; * Have a history of allergic reaction to human biological medicines. * Receipt of live vaccine within 1 month; * Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly). * Have received treatment with B cell targeted therapy such as Rituximab or Epratuzumab etc. * Receipt of anti-tumor necrosis factor#interleukin receptor antagonist# * Receipt of IV immunoglobulin(IVIG),prednisone\>100mg/d more than 14 days or plasma exchange; * There are active infections (such as herpes zoster, human immunodeficiency virus (HIV) virus infection, active tuberculosis, etc.) during the screening period; * Patients have depression or the significant suicide ideation; * Interleukin(IL)-2, thalidomide, Tripterygium wilfordii and traditional Chinese medicine preparation containing Tripterygium Wilfordii were used within 28 days before randomization * Investigator considers candidates not appropriating for the study.